PAUL HEBIG: Open Payments
NPI 1871765768 · VERO BEACH, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,216 in 99 payments from 15 companies in 2025. Trend: 2023 $1,119 · 2024 $1,880 · 2025 $2,216
Food & beverage: $2,216
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 20 | $379 |
| Alkermes, Inc. | 12 | $264 |
| Neurocrine BioSciences, Inc. | 11 | $260 |
| Janssen Pharmaceuticals, Inc | 7 | $205 |
| Teva Pharmaceuticals USA, Inc. | 6 | $187 |
| ABBVIE INC. | 8 | $185 |
| Otsuka America Pharmaceutical, Inc. | 8 | $166 |
| Lundbeck LLC | 8 | $154 |
| E.R. Squibb & Sons, L.L.C. | 6 | $116 |
| Axsome Therapeutics, Inc. | 4 | $108 |
Products named: CAPLYTA, ARISTADA, INGREZZA, REXULTI, AUSTEDO XR, VRAYLAR, COBENFY, INVEGA SUSTENNA.
Industry payments across FL — which companies pay providers there.
